AB0198 EFFICACY AND SAFETY AFTER TRANSITION FROM REFERENCE ADALIMUMAB TO CT-P17 (ADALIMUMAB BIOSIMILAR: 100 MG/ML) IN COMPARISON WITH THE MAINTAINED TREATMENT (CT-P17 OR REFERENCE ADALIMUMAB) IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS: 1-YEAR RESULT

D. Furst,E. Keystone,J. Kay,J. Jaworski, R. Wojciechowski,P. Wiland, A. Dudek,M. Krogulec,S. Jeka,A. Zielinska, J. Trefler, K. Bartnicka-Maslowska, M. Krajewska-Wlodarczyk,P. Klimiuk,S. J. Lee,S. H. Kim,Y. Bae, G. Yang, J. Yoo,T. Kim

ANNALS OF THE RHEUMATIC DISEASES（2021）

Cited 1|Views20

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined